Home

Featured

Revive Therapeutics (RVV.C) incredible patent-portfolio explained

July 4, 2021 by Lukas Kane

Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive […]

The post Revive Therapeutics (RVV.C) incredible patent-portfolio explained appeared first on Equity.Guru.

Mydecine Innovations Group (MYCO.C) psilocybin work with NeuroPharm is a step towards creating a better world

July 16, 2020 by Joseph MortonNeuroPharm War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that it’s the key reason our civilization is advanced as it is. If it weren’t for the catalyst of hundreds of years of continuous war, including the prospect of mutually assured […]

Roadman Investments (LITT.V) really doesn’t want to talk about cedar leaf oil anymore

June 26, 2020 by Joseph Morton One of Roadman Investments (LITT.V) subsidiaries, CLOV Biopharma, recently completed its research program at UBC on cedar leaf oil vapour, but the Securities Exchange Commission (SEC) doesn’t care. The research program has taken a bit longer than the company would have liked, courtesy of COVID-19, but the company’s doctors have acquired most of the exemptions […]

Latest

Red Light (TRIP.C) enters definitive agreement for Mera Life Sciences acquisition

July 30, 2021 by Piers Eaton

Red Light Holland (TRIP.C) announced they have entered into a definitive agreement as part of their acquisition of Mera Life Sciences. Red Light and Mera have entered into an acquisition agreement that would see Red Light acquire 100% of issued and outstanding shares of Mera for a consideration of $2,450,000, which Red Light will pay […]

The post Red Light (TRIP.C) enters definitive agreement for Mera Life Sciences acquisition appeared first on Equity.Guru.

Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses

July 30, 2021 by Piers Eaton

Braxia Scientific (BRAX.C) filed their Q4 and full year-end results for the three and twelve month periods ending on March 31, 2021. At the end of March 2021, Braxia reported $11,395,899 in cash and $18,490,005 in assets, which is up significantly from March 2020, when they had $3,063,693 in cash and assets. That being said, […]

The post Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses appeared first on Equity.Guru.

Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering

July 29, 2021 by Piers Eaton

Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under […]

The post Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering appeared first on Equity.Guru.

Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing

July 29, 2021 by Kieran Robertson

Filament Health (FH.NEO) announced today that it has been granted an amendment to its existing Health Canada Dealer’s License, bolstering the Company’s position at the forefront of natural psychedelic research and manufacturing. “This license amendment significantly increases the scope of our work with natural psychedelics…By studying untapped psychedelics in a scientific setting, we believe we […]

The post Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing appeared first on Equity.Guru.